Puma: 3 Key Takeaways for Long-Term Investors

Puma's U.S. NERLYNX demand is heading toward a second year of growth, yet China royalties are shrinking, a split the company must balance.

TC Trade Conquest Newsroom November 8, 2026 ·1 min read

Key takeaways

On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Puma (PBYI) reported total revenue of $55.1 million for the quarter.
For long-term investors, the business is shifting focus toward clinical drug development while managing international revenue headwinds.
Puma recorded a $2.1 million cumulative reduction to Q3 2026 royalty revenue after generic versions of NERLYNX, its prescription breast cancer drug, gained market share in China.

Puma's U.S. NERLYNX demand is heading toward a second year of growth, yet China royalties are shrinking, a split the company must balance.

See the latest quote, chart and news for PBYI.

Want trade ideas like this in real time? Subscribe to Trade Conquest.